Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-202 phase 1/2 trial in FRα-positive selected solid tumors
2023-506868-14-00Phase 2Authorised
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of farletuzumab ecteribulin and lenvatinib in ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC) and 1 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Recommended phase 2 dose / recommended dose, Objective response rate and 1 more. Planned start Feb 2023; status: authorised.
02
Drugs
farletuzumab ecteribulinlenvatinib
03
Conditions
ovarian cancertriple-negative breast cancer (TNBC)endometrial cancer (EC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506868-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506868-14-00.